OakChart

Alnylam Pharmaceuticals Inc

ALNYHealthcare·Biotechnology·USA·Large·NASD·Nov 11 • 11:01 AM ET

156.20+4.56 (3.01%)
2026-11-11 17:02 CET
Market cap
20,310.36 USD m
Revenue, TTM
5,013.24 USD m
Net income, TTM
2,724.24 USD m
Free cash flow, TTM
752.13 USD m
EPS diluted, TTM
19.80
P/E
7.89
Compare

Price

ALNY against its 20, 50 and 200-day averages
2050200beatmiss
200.00300.00400.005.9M11.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALNYclose 156.2020-day 194.4150-day 223.38200-day 277.34156.20

67.4% under the 52-week high of 479.79 on 3 Dec 2025. 52-week low 149.18 on 10 Nov 2026. Last 15 sessions, 56.1% high to low

Profile

ALNY
52-week range, 2% of the way up
149.18479.79

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

IndexNDX, RUI
Employees2500
IPOMay 28, 2004
Beta0.45
ATR, 14d10.48
Rel volume1.07
Short float4.09%
Insider own0.32%
Inst own102.84%

Snapshot

6 groups

Valuation

IndexNDX, RUI
Market Cap20.92B
Enterprise Value20.33B
Income2.72B
Sales5.01B
Book/sh26.92
Cash/sh26.78
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees2500
IPOMay 28, 2004

Ratios

P/E7.89
Forward P/E17.43
PEG0.25
P/S4.17
P/B5.80
P/C5.83
P/FCF27.82
EV/EBITDA19.68
EV/Sales4.06
Quick Ratio2.43
Current Ratio2.48
Debt/Eq0.83
LT Debt/Eq0.64
Option/ShortYes / Yes

Earnings

EPS (ttm)19.80
EPS next Y8.96
EPS next Q1.72
EPS this Y690.54%
EPS next Y-51.33%
EPS next 5Y68.70%
EPS past 3/5Y- -
Sales past 3/5Y52.98% 49.77%
EPS Y/Y TTM6459.20%
Sales Y/Y TTM56.17%
EPS Q/Q754.21%
Sales Q/Q16.74%
EarningsOct 29 BMO
EPS/Sales Surpr.847.22% 1.92%

Ownership

Insider Own0.32%
Insider Trans-1.29%
Inst Own102.84%
Inst Trans0.76%
ROA42.41%
ROE141.97%
ROIC46.01%
Gross Margin77.28%
Oper. Margin19.50%
Profit Margin54.34%
SMA20-19.65%
SMA50-30.07%
SMA200-43.68%
Trades-

Technical

Shs Outstand133.88M
Shs Float133.51M
Short Float4.09%
Short Ratio2.81
Short Interest5.47M
52W High479.79 -67.44%
52W Low149.18 4.71%
Volatility5.64% 4.96%
ATR (14)10.48
RSI (14)25.45
Beta0.45
Rel Volume1.07
Avg Volume1.95M
Volume563,438

Performance

Perf Week-3.03%
Perf Month-30.21%
Perf Quarter-31.23%
Perf Half Y-46.41%
Perf YTD-60.72%
Perf Year-65.44%
Perf 3Y-3.51%
Perf 5Y-9.74%
Perf 10Y235.63%
Recom1.71
Target Price298.00
Prev Close151.64
Price156.20
Change %3.01%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 02, 2026DowngradeTTruistBuy → Hold$225+44.0%
Oct 30, 2026DowngradeRRaymond JamesStrong Buy → Outperform$315+101.7%
Oct 30, 2026DowngradeBBernsteinOutperform → Mkt Perform$199+27.4%
Oct 29, 2026DowngradeSStifelBuy → Hold$225+44.0%
Oct 15, 2026ResumedUUBSBuy$354+126.6%
Aug 19, 2026InitiatedBBMO Capital MarketsOutperform$318+103.6%
Aug 03, 2026UpgradeRRaymond JamesOutperform → Strong Buy$420+168.9%
May 19, 2026InitiatedCCitigroupBuy$380+143.3%
Mar 16, 2026DowngradeJJefferiesBuy → Hold$330+111.3%
Jan 28, 2026ResumedBBarclaysOverweight$527+237.4%

Peers

Mkt cap
TickerCompanyMkt cap
ARWRArrowhead Pharmaceuticals Inc6.87B
IONSIonis Pharmaceuticals Inc4.78B
BBIOBridgeBio Pharma Inc15.37B
REGNRegeneron Pharmaceuticals Inc94.44B
ARGXArgen X SE ADR60.75B
VRTXVertex Pharmaceuticals Inc136.57B
WVEWave Life Sciences Inc670.58M
BMRNBiomarin Pharmaceutical Inc11.07B
NTLAIntellia Therapeutics Inc1.60B
AMGNAMGEN Inc248.90B

Insider trading

latest 14 of 56
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SUPRAN BRYANEVP, CLO and SecretaryOct 02 '26Sale226.881,758398,85512,807Oct 06 04:12 PM
SUPRAN BRYANOfficerOct 02 '26Proposed Sale226.881,758398,862Oct 02 03:45 PM
PYOTT DAVID E IDirectorJun 01 '26Option Exercise0.003,83005,412Jun 03 04:25 PM
PYOTT DAVID E IDirectorJun 01 '26Sale299.183,8301,145,8531,582Jun 03 04:25 PM
PYOTT DAVID E IDirectorJun 01 '26Proposed Sale299.513,8301,147,123Jun 01 04:25 PM
SCHULMAN AMY WDirectorMay 13 '26Option Exercise70.2011,250789,75023,211May 14 04:17 PM
McLaughlin MelissaChief Human Resources OfficerApr 06 '26Sale330.422,286755,3299,443Apr 07 04:21 PM
McLaughlin MelissaChief Human Resources OfficerApr 02 '26Sale319.591,624519,01411,729Apr 07 04:21 PM
McLaughlin MelissaOfficerApr 06 '26Proposed Sale320.102,286731,749Apr 06 04:05 PM
Garg PushkalEVP Chief R&DMar 05 '26Sale323.962,404778,81218,693Mar 06 04:13 PM
Garg PushkalEVP Chief R&DMar 04 '26Sale323.082,309745,98421,097Mar 06 04:13 PM
Greenstreet YvonneChief Executive OfficerMar 04 '26Sale323.082,933947,58195,695Mar 06 04:13 PM
Poulton Jeffrey V.EVP, Chief Financial OfficerMar 04 '26Sale323.082,468797,35161,805Mar 06 04:12 PM
Tanguler TolgaEVP, Chief Commercial OfficerMar 04 '26Sale323.082,309745,98434,297Mar 06 04:12 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VOVanguard Morningstar Mid-Cap ETFAUM: 107.07B
QQQInvesco QQQ Trust Series 1AUM: 463.98B
VUGVanguard Morningstar Growth ETFAUM: 217.67B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VOTVanguard Morningstar Mid-Cap Growth ETFAUM: 18.66B
IBBiShares Biotechnology ETFAUM: 11.36B
CGGRCapital Group Growth ETFAUM: 25.66B
IWPiShares Russell Mid-Cap Growth ETFAUM: 18.09B
QQQMInvesco NASDAQ 100 ETFAUM: 106.59B

News

latest 14 of 206
  • Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD (Business Wire)
  • Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA (vutrisiran) in ATTR-CM (Business Wire)
  • Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down (BioPharma Dive)
  • Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership (Business Wire)
  • Tax-loss selling candidates: the worst-performing US large caps of 2026 (Investing.com)
  • Loading…
  • Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference (Business Wire)
  • Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA (vutrisiran) at AHA and ISA 2026 (Business Wire)
  • Earnings roundup: AstraZenecas cost cuts, Alnylams slump and Regenerons resilience (BioPharma Dive)
  • FDA Decision Watch: Regeneron And Roches Autoimmune Drugs, Capricors DMD Therapy In Spotlight (Stocktwits)
  • ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays (Stocktwits) -25.13%
  • Alnylam's Tax-Fueled EPS Blowout Masks A Slowing AMVUTTRA Launch And TTR Guidance Pinned To The Low End (Earnings Whispers)
  • Alnylam: Q3 Earnings Snapshot (Associated Press)
  • Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-2915.7201.66015.7201,4581,43123
2026Q22026-07-301.2101.6301.2071,2911,32221
2026Q12026-04-301.5100.8721.5081,1671,11620
2025Q42026-02-120.8201.1561.3681,0971,14920
2025Q32025-10-301.8400.5611.8401,249959.423
2025Q22025-07-31-0.510-0.544-0.507773.69662.8725
2025Q12025-05-01-0.440-0.890-0.443594.19585.1424
2024Q42025-02-13-0.650-0.592-0.649593.17582.6122
2024Q32024-10-31-0.870-0.917-0.868500.92532.9123
2024Q22024-08-01-0.130-1.067-0.133659.83447.2223
2024Q12024-05-02-0.520-1.116-0.523494.33428.0123
2023Q42024-02-15-1.100-1.186-1.098439.72436.9225
2023Q32023-11-021.150-1.4461.152750.53396.7622
2023Q22023-08-03-2.210-1.506-2.214318.75332.2820
2023Q12023-05-04-1.400-1.671-1.403319.29312.2722
2022Q42023-02-23-1.680-1.859-1.683335.04313.1324

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-8.110-7.899-8.110219.75222.13
2020FY-7.460-7.203-7.464492.85475.26
2021FY-7.200-6.444-7.200844.29820.81
2022FY-9.300-8.953-9.2961,0371,013
2023FY-3.520-3.478-3.5251,8281,826
2024FY-2.180-2.061-2.1792,2482,243
2025FY2.3302.4602.3303,7143,751
2026FY-18.420--5,442
2027FY-8.964--6,574
2028FY-11.186--7,704
2029FY-12.378--8,736
2030FY-14.415--9,707

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-09243191,5251,4531,629
2026Q4S2026-11-08244181,5261,4531,629
2026Q4S2026-11-06254181,5271,4531,629
2026Q4S2026-11-04253191,5261,4531,629
2026Q4S2026-11-03254181,5281,4531,629
2026Q4S2026-11-02253191,5231,4531,629
2026Q4S2026-10-30253191,5231,4531,629
2026Q4S2026-10-29253181,5271,4531,629
2026Q4S2026-10-2825551,5721,4591,700
2026Q4S2026-10-2625461,5711,4591,700
2026Q4S2026-10-2325461,5711,4591,700
2026Q4S2026-10-2025551,5721,4591,700
2026Q4S2026-10-1625531,5751,4591,700
2026Q4S2026-10-1425441,5741,4591,700

Estimate history

EPS, annual-5.42-7.57-8.11-7.464-7.2-9.296-3.525-2.1792.3319.7988
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.868-0.649-0.443-0.5071.841.3681.5081.20715.716
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual89.91274.908219.75492.853844.2871037.4181828.2922248.2433713.9375013.24
Period201720182019202020212022202320242025TTM
Sales, quarterly500.919593.166594.189773.6891249.0261097.0331167.1751290.9481458.086
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual99.667101.177112.188116.427120.182123.925125.794129.294132.376133.875
Period201720182019202020212022202320242025MRQ
Shares, quarterly128.841129.294130.311130.977131.791132.376133.444133.734133.875
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue5,013.243,713.942,248.241,828.291,037.42844.29492.85219.7574.91
Cost of Goods Sold Incl. D&A1,139.05681.87323.37310.41168.82140.1478.0525.068.24
Gross Profit3,874.203,032.071,924.871,517.89868.60704.14414.80194.6966.67
Selling, General and Administrative Excl. Other2,896.602,530.492,101.761,800.061,653.671,412.801,243.241,134.12881.34
Research and Development1,558.761,319.781,126.231,004.41883.01792.16654.82655.11505.42
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income977.59501.58-176.88-282.18-785.07-708.65-828.44-939.43-814.67
Interest Expense365.05252.63141.86121.22155.97143.0284.500.00-
Unusual Expense-42.47170.7791.00171.2538.4317.18-9.42-20.56
Net Income Before Taxes856.41323.15-377.38-433.52-1,126.99-852.14-855.60-885.25-760.67
Income Taxes-1,867.839.40-99.226.724.160.682.680.860.82
Consolidated Net Income2,724.24313.75-278.16-440.24-1,131.16-852.82-858.28-886.12-761.50
Net Income From Continuing Operations2,724.24313.75-278.16-440.24-1,131.16-852.82-858.28-886.12-761.50
Net Income2,724.24313.75-278.16-440.24-1,131.16-852.82-858.28-886.12-761.50
EPS (Recurring)19.792.55-1.24-3.01-8.31-6.97-7.36-8.17-7.71
EPS (Basic, Before Extraordinaries)20.392.39-2.18-3.52-9.30-7.20-7.46-8.11-7.57
EPS (Diluted)19.802.33-2.18-3.52-9.30-7.20-7.46-8.11-7.57
EBITDA1,033.03557.24-120.22-228.12-740.60-661.09-793.67-922.26-808.24
Non-Operating Income (Expense)108.37116.67112.1460.88-14.7137.9674.5244.7633.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense242.95275.11214.95175.13182.21120.97102.11127.63124.62
Price To Earnings Ratio7.667.66-------
Price To Sales Ratio6.7914.4213.3613.0827.8823.7930.3257.2697.91
Gross Margin77.2881.6485.6283.0283.7383.4084.1688.6089.00
Operating Margin19.5013.51-7.87-15.43-75.68-83.93-168.09-427.50-1,087.56
Net Margin54.348.45-12.37-24.08-109.04-101.01-174.15-403.24-1,016.58
Shares Outstanding133.88132.38129.29125.79123.92120.18116.43112.19101.18
Market Capitalization20,310.3620,310.3630,350.5224,020.6229,237.6020,281.9415,100.0412,840.307,366.10

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1,458.091,290.951,167.171,097.031,249.03773.69594.19593.17
Cost of Goods Sold Incl. D&A361.75298.45211.12267.72200.15142.9571.04102.82
Gross Profit1,096.34992.50956.05829.311,048.87630.74523.15490.35
Selling, General and Administrative Excl. Other750.54761.06687.42697.59680.89646.93505.07595.51
Research and Development408.54413.13364.87372.22358.81323.62265.12300.17
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income345.80231.44268.64131.72367.98-16.2018.08-105.16
Interest Expense84.3782.0569.29129.3444.4040.2538.6538.97
Unusual Expense0.000.00--135.49103.8115.2658.8970.27
Net Income Before Taxes295.81177.81221.65161.14238.97-35.36-41.60-193.96
Income Taxes-1,871.5313.3115.66-25.28-12.1230.9215.88-110.19
Consolidated Net Income2,167.34164.49205.99186.42251.08-66.28-57.48-83.76
Net Income From Continuing Operations2,167.34164.49205.99186.42251.08-66.28-57.48-83.76
Net Income2,167.34164.49205.99186.42251.08-66.28-57.48-83.76
EPS (Recurring)15.721.211.510.672.37-0.43-0.13-0.27
EPS (Basic, Before Extraordinaries)16.191.231.551.411.91-0.51-0.44-0.65
EPS (Diluted)15.721.211.511.371.84-0.51-0.44-0.65
EBITDA360.27245.34282.19145.22381.79-2.2532.48-90.99
Non-Operating Income (Expense)34.3828.4222.3023.2719.1936.3537.8620.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense62.5068.4355.4256.5985.4988.2344.8072.40
Price To Earnings Ratio7.6671.53146.591,654.12----
Price To Sales Ratio6.798.6610.6714.5919.5117.3014.9113.51
Gross Margin75.1976.8881.9175.6083.9881.5288.0482.67
Operating Margin23.7217.9323.0212.0129.46-2.093.04-17.73
Net Margin148.6412.7417.6516.9920.10-8.57-9.67-14.12
Shares Outstanding133.88133.73133.44132.38131.79130.98130.31129.29
Market Capitalization20,310.3640,191.4243,880.9752,535.1359,772.0242,518.2235,122.5830,350.52

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments2,908.482,694.502,439.382,192.412,437.741,876.861,536.171,084.381,690.62
Short Term Receivables777.57405.31327.79237.96198.57602.4143.0118.7634.00
Inventories82.7278.5189.15128.9686.3675.2056.3524.070.00
Other Current Assets281.89116.96126.38132.9285.9060.3080.3473.4940.12
Total Current Assets4,050.663,295.282,982.702,692.252,808.582,614.781,715.861,200.701,764.74
Net Property, Plant & Equipment708.06693.93725.79738.63733.63706.51646.38320.66181.90
Total Investments and Advances23.7370.8251.5951.5540.8940.7317.2747.0945.42
Deferred Tax Assets185.15178.70-------
Other Assets57.9063.0969.8163.9360.2045.0515.626.362.67
Total Assets5,025.514,301.823,829.883,546.363,643.303,407.062,395.131,574.801,994.73
Short Term Debt Incl. Current Port. of LT Debt265.59154.9096.5082.2677.6350.1927.690.000.00
Accounts Payable115.7288.4255.5298.0973.4351.9749.8859.7128.36
Other Current Liabilities1,085.04942.95815.77587.57544.66483.12275.02119.79115.90
Total Current Liabilities1,466.351,186.27967.79767.91695.71585.27352.59179.49144.25
Long Term Debt2,703.212,588.512,586.122,530.302,108.071,542.54276.1330.0030.00
Provision for Risks Charges0.000.000.000.004.305.204.300.000.00
Deferred Tax Liabilities59.1861.83-------
Other Liabilities7.59398.11496.61406.37247.02257.80323.4163.3454.05
Total Liabilities4,236.334,234.734,050.523,704.583,055.102,390.81956.44272.84228.30
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity789.1867.09-220.64-158.22588.201,016.251,438.691,301.961,766.43
Total Shareholders Equity789.1867.09-220.64-158.22588.201,016.251,438.691,301.961,766.43
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity789.1867.09-220.64-158.22588.201,016.251,438.691,301.961,766.43
Total Liabilities & Stockholders Equity5,025.514,301.823,829.883,546.363,643.303,407.062,395.131,574.801,994.73
Book Value Per Share5.960.52-1.75-1.284.898.7312.8212.8717.72
Tangible Book Value Per Share5.960.52-1.75-1.284.898.7312.8212.8717.72
Full-Time Employees2,5002,2302,1002,0021,6651,4531,3231,065749
Price to Book Ratio5.63937.04-144.77-432.1434.6514.898.985.6711.08
Return on Assets6.73-6.84-11.94-31.47-24.19-29.58-44.64-42.67-30.14
Return on Equity73.28---526.14-106.31-69.92-64.66-49.63-36.54
Return on Invested Capital8.98-10.47-18.61-47.69-31.63-33.54-51.67-57.17-27.32
Quick Ratio2.712.712.993.343.914.344.716.5612.23
Current Ratio2.762.783.083.514.044.474.876.6912.23

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income2,724.24313.75-278.16-440.24-1,131.16-852.82-858.28-886.12-761.50
Depreciation55.4355.6656.6754.0544.4747.5734.7717.186.43
Other Funds (Non Cash)534.34601.65534.02479.58580.97326.39221.25188.13147.35
Funds from Operations1,404.08968.86205.7793.40-505.72-478.87-602.26-680.81-607.72
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-502.31-444.78-214.0810.76-35.55-162.82-12.70402.3845.10
Cash from Operating Activities901.77524.08-8.31104.16-541.27-641.69-614.96-278.43-562.62
Capital Expenditures-149.64-58.70-34.28-62.21-72.06-76.37-70.36-140.16-126.89
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-561.17497.18-82.45-269.70246.11-192.73-359.86-270.52399.83
Purchase of Investments-1,604.81-1,364.86-1,711.99-1,881.98-2,075.41-1,698.26-2,051.53-2,075.93-1,118.87
Sale Or Maturity of Investments1,043.641,862.031,629.541,612.282,321.521,505.531,691.671,805.401,518.70
Other Uses-27.10-2.15-0.12-4.44-4.69-4.20-5.30-7.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-737.90436.33-116.84-336.35169.35-273.30-435.52-417.68272.94
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock103.88250.03302.95147.46259.36246.27299.98853.1865.47
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-3.47
Sale of Common Pref Stock103.88250.03302.95147.46259.36246.27299.98853.1868.94
Proceedsfrom Stock Options0.000.000.000.000.000.0099.50781.900.00
Issuance or Reduction of Debt, Net-53.07-555.220.000.00135.391,000.00686.60-30.000.00
Change in Long Term Debt-53.07-555.220.000.00135.391,000.00686.60-30.000.00
Issuance of Long Term Debt23.32649.280.000.001,016.111,000.00686.600.000.00
Reduction of Long Term Debt-76.39-1,204.500.000.00-880.720.000.00-30.000.00
Net Financing Active Other Cash Flow64.810.00-8.7924.6731.000.858.400.000.00
Other Financing Activities Uses64.810.00-8.790.000.00-18.750.000.000.00
Cash from Financing Activities115.62-305.19294.16172.13425.751,247.12994.98823.1865.47
Exchange Rate Effect-16.4734.94-15.246.39-7.43-9.024.92-0.08-
Net Change in Cash263.01690.15153.77-53.6746.40323.11-50.58127.00-224.20
Free Cash Flow752.13465.38-42.5941.95-613.33-718.07-685.32-418.58-689.50
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow45.28115.08-569.99-----
Deferred Taxes & Investment Tax Credit--2.20-106.760.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments3,587.263,308.153,009.222,908.482,724.622,857.59
Short Term Receivables1,084.90912.74883.96777.57964.77567.11
Inventories105.9197.1184.0382.7275.3871.69
Other Current Assets334.60302.18242.10281.89188.04147.31
Total Current Assets5,112.664,620.174,219.314,050.663,952.813,643.70
Net Property, Plant & Equipment792.86737.50707.56708.06693.14692.19
Total Investments and Advances23.6523.3323.8123.7353.8770.77
Deferred Tax Assets2,006.67113.79116.96185.1598.56104.36
Other Assets58.8363.9761.9157.9053.2855.00
Total Assets7,994.675,558.775,129.555,025.514,851.664,566.02
Short Term Debt Incl. Current Port. of LT Debt679.65304.50273.15265.59160.45143.62
Accounts Payable135.40108.02126.63115.72117.59102.39
Other Current Liabilities1,247.961,099.99949.701,085.041,277.441,054.83
Total Current Liabilities2,063.011,512.511,349.471,466.351,555.481,300.85
Long Term Debt2,317.212,682.992,697.082,703.212,612.862,596.11
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---59.18--
Other Liabilities10.619.157.617.59449.43418.47
Total Liabilities4,390.824,204.654,054.174,236.334,617.774,315.43
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity3,603.851,354.121,075.38789.18233.89250.59
Total Shareholders Equity3,603.851,354.121,075.38789.18233.89250.59
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity3,603.851,354.121,075.38789.18233.89250.59
Total Liabilities & Stockholders Equity7,994.675,558.775,129.555,025.514,851.664,566.02
Book Value Per Share26.9210.138.065.961.771.91
Tangible Book Value Per Share26.9210.138.065.961.771.91
Full-Time Employees---2,500--
Price to Book Ratio5.6337.3555.50224.06238.34368.11
Return on Assets42.4115.9612.366.730.96-7.44
Return on Equity141.97100.7096.9473.2832.73-257.82
Return on Invested Capital36.604.075.465.348.82-2.33
Quick Ratio2.432.993.062.712.492.75
Current Ratio2.483.053.132.762.542.80

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income2,167.34164.49205.99186.42251.08-66.28
Depreciation14.4813.9013.5513.5113.8013.94
Other Funds (Non Cash)157.06173.95139.3863.95259.28146.25
Funds from Operations444.14355.00368.24236.71529.77103.65
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-103.15-28.27-297.73-73.15-204.6650.08
Cash from Operating Activities340.99326.7270.50163.56325.11153.73
Capital Expenditures-69.83-34.68-21.83-23.29-12.14-14.29
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-240.71-302.88-3.71-13.87515.40-127.09
Purchase of Investments-509.60-593.57-265.73-235.91-209.67-468.81
Sale Or Maturity of Investments268.89290.69262.02222.04725.07341.72
Other Uses-1.20-25.900.000.00-2.150.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-311.74-363.46-25.54-37.17501.11-141.38
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock15.4633.5613.1641.7077.7481.22
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock15.4633.5613.1641.7077.7481.22
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net2.892.682.57-61.21-494.010.00
Change in Long Term Debt2.892.682.57-61.21-494.010.00
Issuance of Long Term Debt6.006.006.005.32643.960.00
Reduction of Long Term Debt-3.11-3.32-3.43-66.53-1,137.970.00
Net Financing Active Other Cash Flow-0.00-0.01-0.0164.82-32.08-27.46
Other Financing Activities Uses-0.00-0.01-0.0164.82-32.08-27.46
Cash from Financing Activities18.3536.2415.7145.32-448.3553.76
Exchange Rate Effect-1.26-2.44-7.06-5.70-0.9327.51
Net Change in Cash46.34-2.9453.61166.00376.9493.61
Free Cash Flow271.15292.0448.67140.26312.97139.44
Price to Free Cash Flow45.2852.4371.31116.45282.93-

Revenue breakdown

Collaborations2024: 510.22M 2025: 553.37M
Product2024: 1.65B 2025: 2.99B
Royalty2024: 91.79M 2025: 174.02M
United States2024: 2.25B 2025: 3.71B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.09%5.5M133.5M1.87M
2026-10-154.92%6.6M133.4M1.72M
2026-09-305.78%7.7M133.4M1.80M
2026-09-155.39%7.2M133.4M1.84M
2026-08-314.75%6.3M133.4M1.73M
2026-08-143.58%4.8M133.4M1.62M
2026-07-313.60%4.8M133.2M1.46M
2026-07-154.34%5.8M132.9M1.27M
2026-06-304.36%5.8M132.9M1.13M
2026-06-154.09%5.4M132.9M1.12M
2026-05-293.99%5.3M132.9M1.10M
2026-05-154.06%5.4M132.9M1.13M
2026-04-303.60%4.8M132.6M1.26M
2026-04-153.80%5.0M132.5M1.31M
2026-03-313.85%5.1M131.5M1.39M
2026-03-133.32%4.4M131.5M1.52M
2026-02-273.48%4.6M131.5M1.54M
2026-02-133.99%5.2M131.4M1.53M
2026-01-304.08%5.3M129.6M1.39M
2026-01-154.29%5.6M129.8M1.32M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call90.0064.3067.200.002.0450.000.000.990-0.0690.007
call95.0059.3062.200.001.8690.000.000.989-0.0690.007
call10054.2057.200.001.7320.000.000.988-0.0690.008
call10549.4052.100.001.5630.000.000.986-0.0680.009
call11044.4047.300.001.4880.000.000.985-0.0680.009
call11539.4042.300.001.3320.000.000.930-0.2740.033
call12034.4037.300.001.1810.000.000.922-0.2650.036
call12529.5032.500.001.0910.000.000.913-0.2550.039
call13024.6027.500.000.9420.000.000.883-0.2950.048
call13519.6023.200.000.9340.000.000.866-0.2780.053
call14015.1018.000.000.7170.000.000.846-0.2520.059
call14510.8013.709.800.62020.000.000.810-0.2300.067
call1507.509.607.150.47942.004.000.695-0.2890.086
call1554.905.804.800.5211591.000.562-0.3140.097
call1603.103.703.590.5281013.000.422-0.3110.096
call1651.702.202.050.54822023.000.305-0.2900.086
call1700.851.351.000.5603741.000.194-0.2180.068
call1750.051.200.600.6533090.000.151-0.2100.058
call1800.000.500.660.6033690.000.078-0.1200.036
call1850.001.503.100.69325.000.000.069-0.1270.033
call1900.050.950.490.7744110.000.063-0.1320.031
call1950.051.300.100.8531330.000.058-0.1360.029
call2000.051.200.080.9273090.000.055-0.1400.027
call2100.052.550.551.0681530.000.049-0.1470.025
call2200.000.200.201.23294.000.000.044-0.1540.023
call2300.002.700.101.3431280.000.041-0.1580.021
call2400.002.700.201.2477700.000.019-0.0790.011
call2500.002.700.101.3465150.000.018-0.0810.011
call2600.003.400.501.4391270.000.017-0.0820.010
call2700.002.900.161.5302880.000.016-0.0840.010
call2800.002.800.151.92676.000.000.036-0.2030.019
call2900.003.400.251.6932820.000.015-0.0860.009
call3000.003.000.411.77314.000.000.014-0.0870.009
call3100.003.403.941.8446.000.000.014-0.0880.009
call3200.003.400.551.92343.000.000.013-0.0890.008
call3300.003.401.681.9841.000.000.013-0.0900.008
call3400.003.400.402.0585.000.000.013-0.0910.008
call3500.003.400.002.1140.000.000.012-0.0920.008
call3600.003.401.662.1750.000.000.012-0.0920.008
call3700.003.400.002.2350.000.000.012-0.0930.008
put90.000.003.400.001.6040.000.00-0.010-0.0590.007
put95.000.003.400.001.4490.000.00-0.011-0.0580.007
put1000.002.900.001.3020.000.00-0.013-0.0570.008
put1050.003.400.001.2000.000.00-0.014-0.0570.009
put1100.000.150.201.55741.000.00-0.065-0.2650.031
put1150.002.700.271.43835.000.00-0.070-0.2610.033
put1200.003.500.251.2763.000.00-0.078-0.2510.036
put1250.001.200.400.9162.000.00-0.085-0.1800.039
put1300.003.600.501.08533.000.00-0.120-0.2930.049
put1350.003.700.700.9256.000.00-0.138-0.2740.054
put1400.002.101.400.7841010.00-0.188-0.2800.066
put1451.251.601.250.59690.0013.00-0.197-0.2250.068
put1502.403.103.280.6256644.00-0.305-0.2720.086
put1554.405.208.100.6081,0200.00-0.438-0.2970.097
put1607.308.2011.400.6371650.00-0.578-0.2930.096
put16510.5012.7013.100.7701321.00-0.695-0.2720.086
put17014.4016.5019.510.82537.000.00-0.799-0.2110.069
put17518.5021.4024.530.91975.000.00-0.849-0.1900.058
put18023.2026.1020.601.0281160.00-0.922-0.1000.036
put18528.0031.0028.571.08221.000.00-0.931-0.1060.033
put19033.0035.9034.601.19577.000.00-0.937-0.1100.031
put19537.8040.9038.351.28532.000.00-0.942-0.1150.029
put20042.9045.8044.751.3651,8510.00-0.946-0.1180.027
put21052.9055.8046.811.52634.000.00-0.952-0.1240.025
put22062.9065.8068.971.7522040.00-0.978-0.0500.013
put23072.5076.0073.061.8815020.00-0.980-0.0520.012
put24082.5086.9082.962.1224.000.00-0.981-0.0520.011
put25092.5096.9093.042.2593.000.00-0.982-0.0530.011
put260102.5107102.992.4090.000.00-0.983-0.0530.010
put270112.5116.995.692.5110.000.00-0.984-0.0540.010
put280122.5126.9105.672.6280.000.00-0.985-0.0540.009
put290132.5136.90.002.8370.000.00-0.985-0.0540.009
put300142.5146.90.002.9450.000.00-0.986-0.0540.009
put310152.5156.90.002.9460.000.00-0.986-0.0540.009
put320162.5166.90.003.0430.000.00-0.987-0.0540.008
put330172.51770.003.1800.000.00-0.987-0.0530.008
put340182.5186.90.003.2250.000.00-0.987-0.0530.008
put350192.51970.003.3350.000.00-0.988-0.0530.008
put360202.52070.003.3950.000.00-0.988-0.0530.008
put370212.52170.003.5450.000.00-0.988-0.0520.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-02SEC
2026-11-05SCHEDULE 13G/ASEC
2026-10-30SCHEDULE 13GSEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-19SEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-033Initial statement of beneficial ownership of securities2026-06-01SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-05-278-KCurrent report2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-13SEC
2026-05-06SCHEDULE 13G/ASEC
2026-04-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-308-KCurrent report2026-04-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000398.86K1
2026-090000
2026-080000
2026-070000
2026-06001.15M1
2026-050000
2026-04001.27M2
2026-030010.09M14
2026-02006.97M7
2026-01006.98M6
2025-120000
2025-110017.10M3

Institutional holders

Manager% owned
FMR LLC9.43%
Capital World Investors8.35%
BlackRock, Inc.8.17%
Capital Research Global Investors7.30%
VANGUARD PORTFOLIO MANAGEMENT LLC4.90%
VANGUARD CAPITAL MANAGEMENT LLC4.52%
T. Rowe Price Investment Management, Inc.4.23%
BAILLIE GIFFORD & CO4.10%
Invesco Ltd.2.81%
STATE STREET CORP2.66%

Funds

Fund% owned
Franklin Convertible Securities Fund11.68%
Growth Fund of America6.70%
Fidelity SAI Convertible Arbitrage Fund6.37%
JPMorgan Strategic Income Opportunities Fund5.80%
Fidelity Convertible Securities Fund4.55%
Miller Convertible Bond Fund4.49%
NYLIM VP MacKay Convertible Portfolio4.30%
NYLIM MacKay Convertible Fund4.09%
AMCAP Fund3.38%
Miller Intermediate Bond Fund3.37%

OakChart. ALNY. Cached 15 minutes.